Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Biocept, Inc. (OTC: BIOC).

Full DD Report for BIOC

Recent News from (OTC: BIOC)

Biocept to Webcast Presentation at the 7th Annual MicroCap Conference
SAN DIEGO , April 6, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and...
Source: PR Newswire
Date: April, 06 2018 08:05
Free Post Earnings Research Report: Exact Sciences' Quarterly Revenues Jumped 148.02%
Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS ) ("EXAS"). If you want access to this report all you need to do is sign up now by clicking the...
Source: ACCESSWIRE IA
Date: April, 06 2018 07:40
Biocept to Present at the 7th Annual MicroCap Conference
SAN DIEGO , April 3, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO ...
Source: PR Newswire
Date: April, 03 2018 08:05
Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China
SAN DIEGO , March 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of Chi...
Source: PR Newswire
Date: March, 29 2018 08:05
Biocept's (BIOC) CEO Michael Nall on Q4 2017 Results - Earnings Call Transcript
Biocept, Inc. (BIOC) Q4 2017 Earnings Conference Call March 28, 2018 4:30 p.m. ET Executives Michael Nall - CEO Tim Kennedy - CFO Bruce Voss - LHA IR Analysts Keay Nakae - Chardan Capital Markets Lauren Chung - WestPark Capital Presentation Operator Ladies and g...
Source: SeekingAlpha
Date: March, 28 2018 22:48
Biocept Reports 2017 Fourth Quarter and Full Year Financial Results
SAN DIEGO , March 28, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three an...
Source: PR Newswire
Date: March, 28 2018 16:05
Biocept Inc, Liquid Biopsy is Coming, Analysts Review, Biopsy Market and Upcoming Milestones
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics comp...
Source: ACCESSWIRE IA
Date: March, 28 2018 08:10
Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
SAN DIEGO , March 28, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered in...
Source: PR Newswire
Date: March, 28 2018 08:05
Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit
SAN DIEGO , March 20, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the presentation ...
Source: PR Newswire
Date: March, 20 2018 08:05
Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
SAN DIEGO , March 15, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two abstract...
Source: PR Newswire
Date: March, 15 2018 08:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-210.2430.24360.24990.24483,141
2018-04-200.2430.24360.24990.24483,141
2018-04-190.2550.2430.25920.2401803,786
2018-04-180.24630.24680.2590.2416820,406
2018-04-170.250.250.260.23882,160,983

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About Biocept, Inc. (OTC: BIOC)

Logo for Biocept, Inc. (OTC: BIOC)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $2,644,862 - 03/20/2018
    • Issue and Outstanding: 8,396,387 - 09/29/2016

     


    Recent Filings from (OTC: BIOC)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 28 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 28 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: February, 12 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: February, 01 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: January, 30 2018
    Registration of up to an additional 20% of securities for any offering registered on an S-1
    Filing Type: S-1MEFFiling Source: edgar
    Filing Date: January, 26 2018
    Prospectus filed under Rule 424(b)(4)
    Filing Type: 424B4Filing Source: edgar
    Filing Date: January, 26 2018
    Notice from the SEC of registration effectiveness
    Filing Type: EFFECTFiling Source: edgar
    Filing Date: January, 25 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: January, 24 2018

     

     


    Daily Technical Chart for (OTC: BIOC)

    Daily Technical Chart for (OTC: BIOC)


    Stay tuned for daily updates and more on (OTC: BIOC)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: BIOC)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    The Subway Trader
    @TheSubwayTrader

     

     


    Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIOC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BIOC and does not buy, sell, or trade any shares of BIOC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

     

     

    Release this Report to Investors

    Via Email

    Via Text

    Important

    If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us